We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+33.5%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.54B
AUM Growth
+$235M
Cap. Flow
+$123M
Cap. Flow %
7.98%
Top 10 Hldgs %
73.5%
Holding
35
New
4
Increased
4
Reduced
1
Closed
8

Top Buys

Rank Stock Value
1
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$79.5M
2
IMMU
Immunomedics Inc
IMMU
+$62.7M
3
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$45.3M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$42.2M
5
TGTX icon
TG Therapeutics
TGTX
+$24.8M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$127M
2
GYRE icon
Gyre Therapeutics
GYRE
+$13.3M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$9.37M
4
VKTX icon
Viking Therapeutics
VKTX
+$8.87M
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$6.72M

Sector Composition

Rank Sector Weight
1 Healthcare 92.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARA icon
26
Protara Therapeutics
TARA
$214M
$3.28M 0.21%
33,437
– –
GTHX
27
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.74M 0.11%
40,000
– –
GYRE icon
28
Gyre Therapeutics
GYRE
$629M
– –
-68,656
Closed -$13.3M
KRYS icon
29
Krystal Biotech
KRYS
$10.7B
– –
-496,071
Closed -$5M
PDSB icon
30
PDS Biotechnology
PDSB
$37.4M
– –
-14,275
Closed -$337K
VKTX icon
31
Viking Therapeutics
VKTX
$3.88B
– –
-2,029,396
Closed -$8.87M
VIRX
32
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-70,613
Closed -$6.72M
AVXS
33
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-1,028,289
Closed -$127M
CTIC
34
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-56,951
Closed -$222K
BHVN
35
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-363,636
Closed -$9.37M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, RA Capital Management held 35 positions worth $1.54B, up 18% from $1.31B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

RA Capital Management deployed $123M of net new capital in Q2 2018, opening 4 new positions and adding to 4 existing holdings. Its largest new stake was Momenta Pharmaceuticals, Inc.: 3,702,533 shares worth $75.7M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Sage Therapeutics, an estimated $345K trimmed.

  • RA Capital Management's largest Q2 2018 buy was Momenta Pharmaceuticals, Inc.: 3,702,533 shares worth $75.7M.
  • RA Capital Management added most to TG Therapeutics in Q2 2018, an estimated $24.8M increase.
  • RA Capital Management's biggest Q2 2018 reduction was Sage Therapeutics, cutting an estimated $345K.
  • RA Capital Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $127M.
  • RA Capital Management's ten largest holdings make up 74% of its $1.54B portfolio in Q2 2018.
  • RA Capital Management opened 4 new positions and closed 8 in Q2 2018.
  • RA Capital Management's portfolio value rose 18% quarter-over-quarter to $1.54B.

Based on RA Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.